Biotech Values

[DewDiligence]

GILD – The GS9190 HCV non-nucleoside polymerase-inhibitor program will go forward to phase-2 after all because the phase-1b trial determined that the 40mg BID dose does not cause unacceptable QT-prolongation. A phase-2 trial with 200 patients will start by year-end testing GS9190+SoC for either 24 or 48 weeks vs SoC for 48 weeks. (Source: today’s GILD CC)


<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”